199 related articles for article (PubMed ID: 22622126)
1. [Cardioprotection in women with neoplastic disease].
Cardinale D; Colombo A; Bacchiani G
G Ital Cardiol (Rome); 2012 Jun; 13(6):461-8. PubMed ID: 22622126
[TBL] [Abstract][Full Text] [Related]
2. High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury.
Jones M; O'Gorman P; Kelly C; Mahon N; Fitzgibbon MC
Ann Clin Biochem; 2017 Jan; 54(1):149-157. PubMed ID: 27170025
[TBL] [Abstract][Full Text] [Related]
3. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.
Cardinale D; Colombo A; Sandri MT; Lamantia G; Colombo N; Civelli M; Martinelli G; Veglia F; Fiorentini C; Cipolla CM
Circulation; 2006 Dec; 114(23):2474-81. PubMed ID: 17101852
[TBL] [Abstract][Full Text] [Related]
4. Role of afterload reduction in the prevention of late anthracycline cardiomyopathy.
Silber JH
Pediatr Blood Cancer; 2005 Jun; 44(7):607-13. PubMed ID: 15795884
[TBL] [Abstract][Full Text] [Related]
5. [Cardiotoxicity of anthracyclines].
Costache II; Petriş A
Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
[TBL] [Abstract][Full Text] [Related]
6. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic prevention of anthracycline-induced cardiomyopathy.
Maradia K; Guglin M
Cardiol Rev; 2009; 17(5):243-52. PubMed ID: 19690476
[TBL] [Abstract][Full Text] [Related]
8. Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy.
Janbabai G; Nabati M; Faghihinia M; Azizi S; Borhani S; Yazdani J
Cardiovasc Toxicol; 2017 Apr; 17(2):130-139. PubMed ID: 27003392
[TBL] [Abstract][Full Text] [Related]
9. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention--review of the literature.
Wojtacki J; Lewicka-Nowak E; Leśniewski-Kmak K
Med Sci Monit; 2000; 6(2):411-20. PubMed ID: 11208348
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
Pouillart P
Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
[TBL] [Abstract][Full Text] [Related]
11. [Anthracycline-induced cardiomyopathy].
Roul G; Cohen C; Lieber A
Presse Med; 2009 Jun; 38(6):987-94. PubMed ID: 19423276
[TBL] [Abstract][Full Text] [Related]
12. Cardiac Toxicity: Using Angiotensin-Converting Enzyme Inhibitors to Prevent Anthracycline-Induced Left Ventricular Dysfunction and Cardiomyopathy.
Kobza C
Clin J Oncol Nurs; 2021 Jun; 25(3):259-266. PubMed ID: 34019025
[TBL] [Abstract][Full Text] [Related]
13. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity.
Conklin KA
Integr Cancer Ther; 2005 Jun; 4(2):110-30. PubMed ID: 15911925
[TBL] [Abstract][Full Text] [Related]
14. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy.
Pinarli FG; Oğuz A; Tunaoğlu FS; Karadeniz C; Gökçora N; Elbeg S
Pediatr Blood Cancer; 2005 Apr; 44(4):370-7. PubMed ID: 15602715
[TBL] [Abstract][Full Text] [Related]
15. Role of biomarkers in chemotherapy-induced cardiotoxicity.
Cardinale D; Sandri MT
Prog Cardiovasc Dis; 2010; 53(2):121-9. PubMed ID: 20728699
[TBL] [Abstract][Full Text] [Related]
16. Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies.
Cadeddu C; Mercurio V; Spallarossa P; Nodari S; Triggiani M; Monte I; Piras R; Madonna R; Pagliaro P; Tocchetti CG; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e64-e75. PubMed ID: 27755244
[TBL] [Abstract][Full Text] [Related]
17. A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
Spallarossa P; Maurea N; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e84-e92. PubMed ID: 27755246
[TBL] [Abstract][Full Text] [Related]
18. [Prevention of anthracycline cardiotoxicity].
Rossetti R
Suppl Tumori; 2004; 3(4):S117-9. PubMed ID: 15206234
[No Abstract] [Full Text] [Related]
19. Anthracycline-related cardiotoxicity in childhood cancer survivors.
Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
[TBL] [Abstract][Full Text] [Related]
20. Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
Scully RE; Lipshultz SE
Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]